Hancock Jaffe Laboratories, Inc. (HJLI)
Stock Price:
$0.397 USD
-0.002 (-0.38%)
Updated Jul 9, 2020 9:39 AM EDT - Market open
Key Info
| Market Cap |
9.51M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-7.21M |
| Shares Out |
23.95M |
| EPS (ttm) |
-0.42 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 9, 2020 |
| Last Price |
$0.397 |
| Previous Close |
$0.399 |
| Change ($) |
-0.002 |
| Change (%) |
-0.38% |
| Day's Open |
0.400 |
| Day's Range |
0.396 - 0.400 |
| Day's Volume |
116,974 |
| 52-Week Range |
0.211 - 1.200 |
More Stats
| Market Cap |
9.51M |
| Enterprise Value |
8.77M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
23.95M |
| Float |
18.19M |
| EPS (basic) |
-0.42 |
| EPS (diluted) |
-0.42 |
| FCF / Share |
-0.32 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
44,586 |
| Short Ratio |
0.03 |
| Short % of Float |
0.24% |
| Beta |
1.81 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
9.13 |
| Revenue |
n/a |
| Operating Income |
-7.60M |
| Net Income |
-7.21M |
| Free Cash Flow |
-5.92M |
| Net Cash |
739,863 |
| Net Cash / Share |
0.03 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-106.15% |
| ROE |
-505.99% |
| ROIC |
-3,504.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
3.00
Current: 0.397
High
3.00
Target: 3.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 0.03 | 0.19 | 0.42 | 0.79 |
| Revenue Growth | -83.25% | -55.8% | -46.29% | - |
| Gross Profit | 0.03 | 0.19 | - | -0.02 |
| Operating Income | -7.68 | -7.85 | -6.10 | -4.66 |
| Net Income | -7.63 | -13.04 | -7.79 | -3.39 |
| Shares Outstanding | 15.76 | 9.36 | 6.13 | 6.04 |
| Earnings Per Share | -0.48 | -1.75 | -1.35 | -0.62 |
| Operating Cash Flow | -5.90 | -6.36 | -4.20 | -3.42 |
| Capital Expenditures | -0.36 | -0.01 | -0.01 | - |
| Free Cash Flow | -6.26 | -6.37 | -4.21 | -3.42 |
| Cash & Equivalents | 2.12 | 2.74 | 0.08 | 0.06 |
| Total Debt | 0.86 | - | 2.62 | 0.63 |
| Net Cash / Debt | 1.26 | 2.74 | -2.54 | -0.58 |
| Assets | 3.43 | 3.56 | 2.21 | 1.78 |
| Liabilities | 2.44 | 1.52 | 8.17 | 2.07 |
| Book Value | 0.99 | 2.04 | -11.13 | -4.22 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Hancock Jaffe Laboratories, Inc. |
| Country |
United States |
| Employees |
12 |
| CEO |
Robert Andrew Berman |
Stock Information
| Ticker Symbol |
HJLI |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Medical Devices |
| Unique Identifier |
NASDAQ: HJLI |
Description
Hancock Jaffe Laboratories, Inc., a development stage company, develops and sells biological based tissue solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe. The company develops and manufactures bioprosthetic implantable devices for cardiovascular diseases, including the VenoValve, a porcine based device to be surgically implanted in the deep venous system of the leg to treat chronic venous insufficiency; the CoreoGraft, a bovine based off the shelf conduit to be used to revascularize the heart during coronary artery bypass graft surgeries; and the Bioprosthetic Heart Valve, a porcine based heart valve designed to function like a native heart valve used for pediatric heart valve recipients. It also provides research, development, and contract manufacturing services. Hancock Jaffe Laboratories, Inc. was founded in 1987 and is based in Irvine, California.